FDA has accepted for review the filing of a supplemental New Drug Application for XTANDI (enzalutamide) to add an indication for the treatment of men with metastatic hormone-sensitive prostate cancer.
Early endpoints have the potential to get effective drugs to patients faster, but granting approval to drugs—even accelerated approval—comes with the risk that ineffective or even harmful drugs will be given to patients.
